 OBJECTIVE: To determine the proportion of patients with continued clinical response CCR and endoscopic remission at week 108, after discontinuation or de-escalation of golimumab treatment at year 1 in the subgroup of patients in continuous clinical response CCR and with mucosal healing MH endoscopic Mayo score of 0 or 1 at week 54. 